title: Docetaxel and epirubicin plus G-CSF mobilize hematopoietic progenitors in breast cancer.
authors.forename: L
authors.initials: L
authors.lastname: Pierelli
authors.forename: G
authors.initials: G
authors.lastname: Leone
authors.forename: E
authors.initials: E
authors.lastname: Cortesi
authors.forename: O
authors.initials: O
authors.lastname: Martelli
authors.forename: A
authors.initials: A
authors.lastname: Perillo
authors.forename: S
authors.initials: S
authors.lastname: Mancuso
authors.forename: G
authors.initials: G
authors.lastname: Scambia
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000077143:Docetaxel; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives; D043823:Taxoids
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; D000077143:Docetaxel; D015251:Epirubicin; D017239:Paclitaxel